Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Rice

Orthopaedic Surgery Layton, UT Medical Doctor

NPI 1730166182 CMS profile 215033

2121 N 1700 W, Layton, UT 84041

Open in the dashboard

General payments

$11,041

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Rice of Layton, UT is reported in the CMS Open Payments database as having received $11,041 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $199 7
2024 General $672 15
2023 General $2,140 29
2022 General $164 7
2021 General $4,117 9
2020 General $3,210 16
2019 General $538 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Rice
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Robert Rice were reported at $199. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Robert Rice Orthopaedic Surgery median Middle half National median
2019 $538 $644 $140–$2,844 $163
2020 $3,210 $312 $75–$1,860 $114
2021 $4,117 $520 $117–$2,495 $132
2022 $164 $598 $128–$2,731 $149
2023 $2,140 $461 $128–$2,264 $160
2024 $672 $497 $134–$2,475 $164
2025 $199 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $7,103 16 payments
  2. Active Medical, LLC $1,877 7 payments
  3. Smith+Nephew, Inc. $292 7 payments
  4. Zimmer Biomet Holdings, Inc. $202 2 payments
  5. Vericel Corporation $171 9 payments
  6. Globus Medical, Inc. $148 6 payments
  7. Miach Orthopaedics, Inc. $145 1 payment
  8. Ferring Pharmaceuticals Inc. $141 10 payments
  9. DePuy Synthes Sales Inc. $125 5 payments
  10. Bioventus LLC $102 6 payments
  11. Other $736 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 3 payments
  2. Food and Beverage $3,004 96 payments
  3. Travel and Lodging $1,109 3 payments
  4. Education $929 1 payment
Products named General payments · program years 2019–2025
  1. EUFLEXXA $141 10 payments
  2. MACI Orthopedics $96 5 payments
  3. LENS 4K $94 1 payment
  4. PREVENA $84 4 payments
  5. NOVOSTITCH $82 2 payments
  6. Durolane $75 4 payments
  7. ORTHOVISC $71 2 payments
  8. MONOVISC $71 2 payments
  9. MACI Cellular Therapy $63 3 payments
  10. FLOW 50/90 $63 1 payment
  11. Other $1,450 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$50,149

Of which drugs: $8,355

Medicare patients

96

Average age 72

Services billed

5,161

38 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 66%
High blood pressure 65%
Diabetes 35%
Depression 32%
Ischemic heart disease 26%
Chronic kidney disease 23%
Atrial fibrillation 22%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 16 1,440 $7,231
Injection, methylprednisolone acetate, 1 mg J1010 Office 20 3,101 $317
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 25 290 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record